SCHEMBL10459531

SCHEMBL10459531

O=C(Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(O)[C@@H]1OC(=S)N1CCS(=O)(=O)CC1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 7/20 0.49
▸ LMNA P02545 2/20 0.48
▸ SLC29A1 Q99808 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ GLA P06280 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ NPY1R P25929 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ NPY2R P49146 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ ADORA3 P0DMS8 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10462621 1.00 ADORA1 (0.49) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL19880313 0.87 ADORA1 (0.49) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL10462010 0.87 ADORA1 (0.51) ADORA1SLC29A1PMP22HTTRXFP1
SCHEMBL10457914 0.87 ADORA1 (0.51) ADORA1SLC29A1PMP22HTTRXFP1
SCHEMBL13838270 0.86 TYMP (0.49) P2RY12
SCHEMBL13830309 0.86 TYMP (0.49) P2RY12
SCHEMBL20798309 0.86 TYMP (0.49) P2RY12
SCHEMBL29479253 0.85 LMNA (0.57) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL29479250 0.85 LMNA (0.57) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL1582757 0.82 MEN1 (0.63) ADORA1LMNASLC29A1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 — — US disclosed
US-9896472-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2018-02-20 — — US disclosed
US-9273086-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2016-03-01 — — US disclosed
US-9273086-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2016-03-01 — — US disclosed
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis AGILENT TECHNOLOGIES, INC. 2016-01-07 — — US disclosed
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis AGILENT TECHNOLOGIES, INC. 2016-01-07 — — US disclosed
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-11-15 — — US disclosed
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, SNRPB2, RNGTT ADORA1 2593/4885LMNA 366/4885SLC29A1 1209/4885
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT ADORA1 4025/4885LMNA 260/4885SLC29A1 1026/4885
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis NSUN2, SNRPB2, RNGTT ADORA1 2593/4885LMNA 366/4885SLC29A1 1209/4885
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS RNMT, RNGTT, NSUN2 ADORA1 2120/4885LMNA 428/4885SLC29A1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback